Eli Lilly and Co
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Evacetrapib and Rifampin in Healthy Participants
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT01908582
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Evacetrapib (LY2484595) in Healthy Participants
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT01903434
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT01900652
- Locations
- ๐บ๐ธ
UCLA, Santa Monica, California, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธUniversity of Iowa Hospital, Iowa City, Iowa, United States
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2129
- Registration Number
- NCT01900665
- Locations
- ๐บ๐ธ
Neurology Center of North Orange County, Fullerton, California, United States
๐บ๐ธPharmaSite Research Inc, Baltimore, Maryland, United States
๐บ๐ธSenior Clinical Trials, Inc., Laguna Hills, California, United States
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: LY2875358Drug: Erlotinib
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT01897480
- Locations
- ๐ฉ๐ฐ
Herlev and Gentofte Hospital, Herlev, Hovedstaden, Denmark
๐ซ๐ทCHU de Caen Hopital Cote de Nacre, Caen, France
๐ซ๐ทCHU De Grenoble Hopital Albert Michallon, Grenoble Cedex 09, France
A Study of Evacetrapib and Digoxin in Healthy Participants
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01897493
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of Baricitinib and Birth Control Pills in Healthy Females
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01896726
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 388
- Registration Number
- NCT01894568
- Locations
- ๐จ๐ณ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yongkang City, Taiwan
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 78
- Registration Number
- NCT01893281
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States
A Study of LY3015014 in Participants With High Cholesterol
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 527
- Registration Number
- NCT01890967
- Locations
- ๐ต๐ท
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico